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Background: The heat shock protein (HSP) inducer, geranylgeranylacetone (GGA), was 
previously found to protect against atrial fibrillation (AF) remodeling in experimental model 
systems. Clinical application of GGA in AF is limited, due to low systemic concentrations 
owing to the hydrophobic character of GGA.
Objectives: To identify novel HSP-inducing compounds, with improved physicochemical 
properties, that prevent contractile dysfunction in experimental model systems for AF.
Methods: Eighty-one GGA-derivatives were synthesized and explored for their HSP-inducing 
properties by assessment of HSP expression in HL-1 cardiomyocytes pretreated with or without 
a mild heat shock (HS), followed by incubation with 10 µM GGA or GGA-derivative. Subse-
quently, the most potent HSP-inducers were tested for preservation of calcium transient (CaT) 
amplitudes or heart wall contraction in pretreated tachypaced HL-1 cardiomyocytes (with or 
without HSPB1 siRNA) and Drosophilas, respectively. Finally, CaT recovery in tachypaced 
HL-1 cardiomyocytes posttreated with GGA or protective GGA-derivatives was determined.
Results: Thirty GGA-derivatives significantly induced HSPA1A expression after HS, and seven 
showed exceeding HSPA1A expression compared to GGA. GGA and nine GGA-derivatives 
protected significantly from tachypacing (TP)-induced CaT loss, which was abrogated by HSPB1 
suppression. GGA and four potent GGA-derivatives protected against heart wall dysfunction after 
TP compared to non-paced control Drosophilas. Of these compounds, GGA and three GGA-
derivatives induced a significant restoration from CaT loss after TP of HL-1 cardiomyocytes.
Conclusion: We identified novel GGA-derivatives with improved physicochemical properties 
compared to GGA. GGA-derivatives, particularly GGA*-59, boost HSP expression resulting 
in prevention and restoration from TP-induced remodeling, substantiating their role as novel 
therapeutics in clinical AF.
Keywords: atrial fibrillation, heat shock protein, Drosophila, proteostasis, geranylger anylacetone
Introduction
Atrial fibrillation (AF) is the most common human cardiac arrhythmia with a prevalence 
of 2.7–6.1 million and 6.5–12.3 million in the USA and European Union, respectively, 
in 2010. This prevalence is expected to rise significantly due to the aging population.1 
AF is a persistent disease, characterized by progressive electrical, structural, and con-
tractile remodeling of cardiomyocytes, also referred to as electropathology.2,3 Current 
AF therapies are symptomatic and aim for rate control but do not prevent expansion of 
the arrhythmogenic substrate.4,5 As a consequence, most patients eventually develop 
longstanding persistent AF, which leads to a substantial increase in cardiac morbidity 
and mortality and warranty of life-long anticoagulant therapy. Despite extensive 
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investigation of the molecular substrate of cardiac remodeling 
in AF, no effective therapy is available to date.
Research by us and others provide evidence that derail-
ment of proteostasis is a key factor underlying electropathol-
ogy and AF progression.6–10 Proteostasis, the homeostasis of 
protein production, function, and breakdown, is important for 
proper cell function. Accordingly, derailment of proteostasis 
is associated with AF but also with many age-related protein-
misfolding diseases, including Alzheimer’s, Parkinson’s, and 
Huntington’s disease.11 Derailment of proteostasis contributes 
importantly to cardiomyocyte remodeling and predisposes to 
AF in experimental models and in AF patients.6,7,9 The most 
important chaperones to maintain a balanced proteostasis are 
the heat shock proteins (HSPs). During stress, the heat shock 
response (HSR) is stimulated by activation of heat shock (HS) 
transcription factors, of which heat shock factor 1 (HSF1) 
is the major regulator of HSP transcription in eukaryotes.12 
HSPs consist of five HSP families, ie, HSPA (HSP70), 
HSPB (small HSPs), HSPC (HSP90), HSPD (HSP60), 
and DnaJB (HSP40), each with several family members, 
(specific) co-factors in various cellular localizations, with 
distinct and overlapping functions.13,14 The family of HSPBs 
is probably the most important in maintaining proteostasis 
in cardiomyocytes.15 Cardiomyocytes express high levels 
of HSPBs which localize with contractile and microtubule 
proteins, thereby stabilizing the cardiomyocyte structure, and 
conserving the contractile and electrophysiological function 
of the atrial cardiomyocytes.16–20 Although HSPB1 levels are 
induced in atrial tissue samples of patient with paroxysmal 
AF, HSPB1 levels get exhausted in patients with (longstand-
ing) persistent AF. In addition, in these patients, HSPB1 levels 
in atrial tissue correlate inversely with the amount of structural 
remodeling, suggesting that the HSR becomes exhausted in 
time resulting in derailment of proteostasis, structural remod-
eling, and AF progression.10,16 In line, boosting of the endog-
enous HSR with drugs may constitute an emerging therapeutic 
strategy for clinical AF. Securing HSP levels at an adequate 
level may limit the expansion of the AF substrate for the 
induction of AF and the ensuing progression of paroxysmal 
to persistent AF.8 A well-known HSP-inducing compound is 
geranylgeranylacetone (GGA). GGA is a nontoxic acyclic iso-
prenoid compound with a retinoid skeleton that is originally 
used as an antiulcer drug in Asian countries.21,22 GGA induces 
HSPs in various tissues, including gastric mucosa, intestine, 
liver, myocardium, retina, and central nervous system.23,24 
The protective effect of GGA-induced HSP expression on 
tachycardia-induced cardiomyocyte remodeling has been 
observed in atrial cardiomyocytes, and a Drosophila model 
for AF, suggesting that the induction of HSPs by GGA might 
have potential value for clinical AF.7,16,25,26 Furthermore, 
GGA treatment protected from cardiomyocyte remodeling 
and tachypacing (TP)-induced AF promotion in a dog model 
for (acute) atrial ischemia and in a heart failure model in 
rabbits.7,27,28 Notwithstanding the protective effects, the poor 
physicochemical properties of GGA, including its lipophilic 
nature (LogP value 6.54) and limited solubility, pose a serious 
disadvantage to its drugability. The gut mucosal distribution 
pattern owing to GGA’s hydrophobic character hinders its 
systemic bioavailability29,30 and consequently a relative high 
daily oral dosage of 120 mg/kg was required to treat dogs.7 
To overcome these disadvantages, various GGA-derivatives 
with improved physicochemical properties were synthesized 
and tested for their ability to induce an HSR in HL-1 cardio-
myocytes and confer protection against TP-induced contrac-
tile dysfunction in HL-1 cardiomyocytes and Drosophila. 
Furthermore, favorable GGA-derivatives were studied on 
their improvement of recovery from contractile dysfunction 
in tachypaced HL-1 cardiomyocytes.
Materials and methods
synthesis of gga-derivatives
The synthesis of the most potent GGA-derivatives is 
described in Supplementary materials.
hl-1 mouse atrial cardiomyocytes 
culture, TP, and caT measurements
HL-1 atrial cardiomyocytes, derived from adult mouse atria, 
were obtained from Dr William Claycomb (Louisiana State 
University, New Orleans, USA, institutional approved MTA 
with laboratory of Brundel)31 and maintained as described 
previously.9 HL-1 cardiomyocytes, seeded on coverslips, 
were subjected to TP as described before7,16 and calcium 
transient (CaT) were measured. Detailed description can be 
found in Supplementary materials.
gga and gga-derivative treatment 
and hs
HL-1 cardiomyocytes, seeded into six wells plates, were 
treated with 10 µM GGA or GGA-derivative or control 
(dimethylsulfoxide, DMSO). For a more detailed description 
on drug and HS treatment, see Supplementary materials.
Drosophila TP and drug treatment
Wild-type W1118 Drosophila larvae were treated with 100 µM 
GGA or GGA-derivatives, prepupae were tachypaced, and 
heart wall contractions were assessed, as described in more 
detail in Supplementary materials.
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Protein isolation and Western blot analysis
HL-1 cardiomyocytes were lysed and equal amounts of pro-
tein were analyzed by Western blot analysis as described in 
detail in Supplementary materials.
rna isolation and Pcr analysis
Total RNA was extracted from HL-1 cardiomyocytes and 
PCR analysis (for primers see Table 1) was performed 
according to the procedures as described in Supplementary 
materials.
sirna hsPB1 knock-down
HL-1 cardiomyocytes were transfected with CD8 and siRNA-
HSPB1 constructs or mock siRNA and subsequently treated 
with GGA or GGA-derivatives before TP and CaT measure-
ments. Refer to Supplementary materials for a complete 
description of the procedures.
statistics
Data are presented as mean ± SD or SEM. All experiments 
were performed at least in duplicate series. Individual group 
mean differences were evaluated with the Student’s t-test. 
Multiple-group comparisons were obtained by ANOVA with 
Bonferroni-corrected post hoc t-tests. A 2-tailed P,0.05 was 
considered statistically significant. GraphPad version 7 was 
used for all statistical evaluations.
Results
synthesis of a gga-derivative library
In order to overcome the high lipophilicity of GGA, we first 
truncated the east side of the molecule to geranylacetone 
(GA) (Figure 1). Based on this parent structure, a library of 
81 compounds was prepared, considering the Lipinski rule 
of five32 (Table 2). Not only the east and west sides of the 
molecule were varied but also several bio-isosters of the 
central keto-moiety of GA were designed and prepared. 
The keto-moiety of GGA and truncated derivatives was 
replaced by isosteric groups, such as oxime, amide, sulfon-
amide, ester, hydroxyl, pyrazolone, pyrazole, and oxazole 
moieties. For the east and west side variations, different alkyl 
chains were chosen, sometimes containing additional func-
tional groups (hydrogen bond donors and acceptors), includ-
ing aromatics. The strategy used to prepare GGA-derivatives 
is depicted in Figure 1; see Supplementary materials for a 
detailed description of synthesis. Following this strategy, 
almost all GGA-derivatives reveal an improved LogP value, 
compared to the mother compound GGA (LogP 6.54), having 
a molecular weight below 500 (Table 2).
gga and gga-derivatives boost 
hsF1-related hsP expression in hl-1 
cardiomyocytes
HSP-inducing properties of the 81 synthesized GGA- 
derivatives and GGA were explored in HL-1 cardiomyocytes 
(Table 2). Since HSPA1A is expressed at low basal levels 
(compared to abundant basal levels of HSPB1) in nonstressed 
control HL-1 cardiomyocytes and becomes strongly upregu-
Table 1 Primers for real-time reverse-transcriptase Pcr
Protein Forward Reverse
hsPa1a (hsP70) 5′ – caTcaagaaggTggTgaagc – 3′ 5′ – accacccTgTTgcTgTag – 3′
hsPB1 (hsP25) 5′ – TgTaTTTccgggTgaagcac – 3′ 5′ – cagTgaagaccaaggaaggc – 3′
hsPca (hsP90) 5′ – aTTggTTggTcTTgggTcTg – 3′ 5′ – gccagTTgcTTcagTgTccT – 3′
DnaJB1 (hsP40) 5′ – TccgTggaaTgTgTagcTga – 3′ 5′ – gaTTTTcgaccgcTaTggag – 3′
hsPa5 (grP75) 5′ – aTcTTTggTTgcTTgTcgcT – 3′ 5′ – aTgaaggagacTgcTgaggc – 3′
glyceraldehyde 3-phosphate dehydrogenase (gaPDh) 5′ – gcaaggagaagcagcagagT – 3′ 5′ – TTTgTgTTTggacTcTcccc – 3′
**$2 2
:HVWVLGH 5 5; (DVWVLGH
&RUH5
Figure 1 Design and synthesis of a compound library based upon gga/ga.
Note: The east side of the molecule to ga was truncated, variations were made at 
the east and west sides of the molecule, and several bio-isosters of the central keto 
moiety were prepared.
Abbreviations: ga, geranylacetone; gga, geranylgeranylacetone.
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Table 2 Overview of physicochemical, hsP-inducing properties, and cardioprotective effects of gga-derivatives in hl-1  
cardiomyocyte model and Drosophila
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga 2 c23h38O 330.56 6.54 √  37±15 ,0.01 Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
Fa 2 c18h30O 262.43 5.02 √  0.6±0.4   
ga 2 c13h22O 194.32 3.49 √  39±17 ,0.01  
gga analog gga*-01 2 c24h40O 344.57 7.2 √  0.52±0.32  
gga*-02 2 c19h32O 276.46 5.67 √  1±1.07  
gga*-03 ) 2)) c23h35F3O 384.52 7.03 √  0.25±0.08  
gga*-04 2)) ) c18h27F3O 316.4 5.5 √  52±19 ,0.01  
gga*-05 2)) ) c13h19F3O 248.28 3.97 √  78±11 ,0.01  
gga*-06 2 c29h42O 406.64 7.72 √  43±11 ,0.01  
gga*-07 2 c24h40O 344.57 7.11 √  32±9 ,0.01  
geranyl oxims gga*-08 +2 1 c13h23nO 209.33 3.88 √ √ 0.57±0.54  
and keto-iso-oxalzoles gga*-09 &+2 1 c14h25nO 223.35 4.14 √  0.57±0.7  
gga*-10 2+1 c23h39nO 345.56 6.93 √ √ 0.5±0.16  
gga*-11 1 2&+ c24h41nO 359.59 7.19 √  0.48±0.07  
geranyl keto-esters gga*-12 22 2 c16h26O3 266.38 3.16 √  0.44±0.08  
gga*-13 22 2 c17h28O3 280.4 3.72 √  0.52±0.4  
gga*-14 22 2 c23h32O3 356.5 5.33 √  160±21 ,0.0001 no  
gga*-15 222 c21h36O3 336.51 5.39 √  0.33±0.08  
gga*-16 2 2 2 c18h30O3 294.43 4.14 √  0.37±0.2  no
gga*-17 2 2 2 c19h32O3 308.46 4.56 √  0.41±0.2  
gga*-18 2 2 2 c18h30O3 294.43 4.43 √  101±14 ,0.001 Yes ,0.0001  no
(Continued)
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Table 2 Overview of physicochemical, hsP-inducing properties, and cardioprotective effects of gga-derivatives in hl-1  
cardiomyocyte model and Drosophila
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga 2 c23h38O 330.56 6.54 √  37±15 ,0.01 Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
Fa 2 c18h30O 262.43 5.02 √  0.6±0.4   
ga 2 c13h22O 194.32 3.49 √  39±17 ,0.01  
gga analog gga*-01 2 c24h40O 344.57 7.2 √  0.52±0.32  
gga*-02 2 c19h32O 276.46 5.67 √  1±1.07  
gga*-03 ) 2)) c23h35F3O 384.52 7.03 √  0.25±0.08  
gga*-04 2)) ) c18h27F3O 316.4 5.5 √  52±19 ,0.01  
gga*-05 2)) ) c13h19F3O 248.28 3.97 √  78±11 ,0.01  
gga*-06 2 c29h42O 406.64 7.72 √  43±11 ,0.01  
gga*-07 2 c24h40O 344.57 7.11 √  32±9 ,0.01  
geranyl oxims gga*-08 +2 1 c13h23nO 209.33 3.88 √ √ 0.57±0.54  
and keto-iso-oxalzoles gga*-09 &+2 1 c14h25nO 223.35 4.14 √  0.57±0.7  
gga*-10 2+1 c23h39nO 345.56 6.93 √ √ 0.5±0.16  
gga*-11 1 2&+ c24h41nO 359.59 7.19 √  0.48±0.07  
geranyl keto-esters gga*-12 22 2 c16h26O3 266.38 3.16 √  0.44±0.08  
gga*-13 22 2 c17h28O3 280.4 3.72 √  0.52±0.4  
gga*-14 22 2 c23h32O3 356.5 5.33 √  160±21 ,0.0001 no  
gga*-15 222 c21h36O3 336.51 5.39 √  0.33±0.08  
gga*-16 2 2 2 c18h30O3 294.43 4.14 √  0.37±0.2  no
gga*-17 2 2 2 c19h32O3 308.46 4.56 √  0.41±0.2  
gga*-18 2 2 2 c18h30O3 294.43 4.43 √  101±14 ,0.001 Yes ,0.0001  no
(Continued)
Drug Design, Development and Therapy 2019:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
350
van Marion et al
Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-19 2+2 22 2 c18h28O5 324.41 2.74 √  0.4±0.2  
gga*-20 2 2 2 c23h30O3 354.48 5.09 √  15±7 ,0.05  
gga*-21 22 22 2 c20h32O5 352.45 3.34 √  13±5 ,0.05  
gga*-22 2 2 2 c6h10O3 130.14 -0.13 √  0.3±0.2  
gga*-23 2 2 2 c16h30O3 270.41 4.1 √  17±4  
gga*-24 2 2 2 c22h30O3 342.47 4.76 √  0.5±0.3  
gga*-25 22+ 2 c19h22O3 298.38 4.15 √ √ 0.4±0.2  
gga*-26 22 22+ c21h28O4 344.44 4.48 √ √ 31±10 ,0.01 Yes ,0.01  
gga*-27 22 2 c16h26O3 266.38 3.07 √  0.3±0.1  
Pyrazolones gga*-28 +2 1+1 c14h22n2O 234.34 3.92 √ √ 78±8 ,0.01 Yes ,0.0001 no  no
gga*-29 +2 11 c15h24n2O 248.36 4.15 √ √ 0.4±0.4  
gga*-30 12+ 1 c21h28n2O 324.46 5.89 √ √ 0.5±0.2  
Diketones gga*-31 2 2 c15h24O2 236.35 1.09 √  155±20 ,0.0001 Yes ,0.0001 Yes ,0.05 Yes ,0.05
geranyl ketones i gga*-32 2 c14h24O 208.34 4.14 √  32±16 ,0.01 Yes ,0.05  
gga*-33 2 c15h26O 222.37 4.56 √  1±1  
gga*-34 2 c16h28O 236.39 4.98 √  15±12 ,0.05  
gga*-35 2 c17h30O 250.42 5.4 √  14±10 ,0.05  
gga*-36 2 c15h26O 222.37 4.71 √  0.5±0.08  
geranyl ketones ii gga*-37 2 c20h28O 284.44 5.75 √  0.3±0.3  
gga*-38 2 c18h32O 264.45 5.81 √  0.5±0.56  
gga*-39 2 c15h24O2 220.35 4.21 √  0.4±0.5   
(Continued)
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Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-19 2+2 22 2 c18h28O5 324.41 2.74 √  0.4±0.2  
gga*-20 2 2 2 c23h30O3 354.48 5.09 √  15±7 ,0.05  
gga*-21 22 22 2 c20h32O5 352.45 3.34 √  13±5 ,0.05  
gga*-22 2 2 2 c6h10O3 130.14 -0.13 √  0.3±0.2  
gga*-23 2 2 2 c16h30O3 270.41 4.1 √  17±4  
gga*-24 2 2 2 c22h30O3 342.47 4.76 √  0.5±0.3  
gga*-25 22+ 2 c19h22O3 298.38 4.15 √ √ 0.4±0.2  
gga*-26 22 22+ c21h28O4 344.44 4.48 √ √ 31±10 ,0.01 Yes ,0.01  
gga*-27 22 2 c16h26O3 266.38 3.07 √  0.3±0.1  
Pyrazolones gga*-28 +2 1+1 c14h22n2O 234.34 3.92 √ √ 78±8 ,0.01 Yes ,0.0001 no  no
gga*-29 +2 11 c15h24n2O 248.36 4.15 √ √ 0.4±0.4  
gga*-30 12+ 1 c21h28n2O 324.46 5.89 √ √ 0.5±0.2  
Diketones gga*-31 2 2 c15h24O2 236.35 1.09 √  155±20 ,0.0001 Yes ,0.0001 Yes ,0.05 Yes ,0.05
geranyl ketones i gga*-32 2 c14h24O 208.34 4.14 √  32±16 ,0.01 Yes ,0.05  
gga*-33 2 c15h26O 222.37 4.56 √  1±1  
gga*-34 2 c16h28O 236.39 4.98 √  15±12 ,0.05  
gga*-35 2 c17h30O 250.42 5.4 √  14±10 ,0.05  
gga*-36 2 c15h26O 222.37 4.71 √  0.5±0.08  
geranyl ketones ii gga*-37 2 c20h28O 284.44 5.75 √  0.3±0.3  
gga*-38 2 c18h32O 264.45 5.81 √  0.5±0.56  
gga*-39 2 c15h24O2 220.35 4.21 √  0.4±0.5   
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Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-40 2 c8h14O 126.2 1.96 √  0.65±0.3   
gga*-41 2 c19h26O 270.41 5.1 √  0.62±0.2   
gga*-42 2 2+ c13h22O2 210.31 2.43 √ √ 0.42±0.008  
gga*-43 2 2 c13h20O2 208.3 2.29 √  0.9±0.8  
gga*-44 22+2 c15h24O3 252.35 5.75 √  13±3 ,0.05  
Pyrazoles/isoxazoles gga*-45 N N H c15h24n2 232.36 4.3 √ √ 15±5 ,0.05  
gga*-46 N N c16h26n2 246.39 4.53 √  14±8 ,0.05  
gga*-47
N N
CN c18h27n3 285.43 4.57 √  0.4±0.5  
gga*-48
N N
OH c17h28n2O 276.42 4.01 √ √ 0.5±0.3  
gga*-49 N O c15h23nO 233.35 4.37 √  0.4±0.2  
gga*-50
N N
F c21h27Fn2 326.45 6.35 √  0.3±0.2  
gga*-51
N N
F c21h27Fn2 326.45 6.35 √  0.6±0.4  
gga*-52
N N
CN c22h27n3 333.47 6.23 √  0.4±0.2  
isosters gga*-53 O
N
H
c12h21nO 195.3 2.04 √ √ 0.6±0.3  
gga*-54 O
N
H
N
H
c13h24n2O 222.34 2.29 √ √ 0.4±0.3  
gga*-55 O
F N
H
N
H
c17h23Fn2O 290.38 3.77 √ √ 0.3±0.2  
gga*-56 O
O
HO N
H
c14h23nO3 253.34 1.71 √ √ 33±8 ,0.01 no  
gga*-57 212 c14h21nO2 235.32 1.96 √ √ 90±12 ,0.001 Yes ,0.0001  no
gga*-58 1 2 1+ c14h26n2O 238.37 1.86 √ √ 95±14 ,0.001 Yes ,0.0001 no  Yes ,0.01
gga*-59 622 1+ c11h21nO2s 231.35 1.59 √ √ 157±19 ,0.0001 Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
gga*-60 6)& 22 1+ c11h18F3nO2s 285.33 3.77 √ √ 162±21 ,0.0001 Yes ,0.0001 Yes ,0.0001 Yes ,0.01
gga*-61 622 1+ c17h25nO2s 307.45 4.26 √ √ 15±5 ,0.05  
gga*-62 622 2(W2 c15h26O4s 302.43 2.14 √  0.3±0.2  
gga*-63 62 22 1+ c13h23nO3s 273.39 0.69 √ √ 0.4±0.3  
(Continued)
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Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-40 2 c8h14O 126.2 1.96 √  0.65±0.3   
gga*-41 2 c19h26O 270.41 5.1 √  0.62±0.2   
gga*-42 2 2+ c13h22O2 210.31 2.43 √ √ 0.42±0.008  
gga*-43 2 2 c13h20O2 208.3 2.29 √  0.9±0.8  
gga*-44 22+2 c15h24O3 252.35 5.75 √  13±3 ,0.05  
Pyrazoles/isoxazoles gga*-45 N N H c15h24n2 232.36 4.3 √ √ 15±5 ,0.05  
gga*-46 N N c16h26n2 246.39 4.53 √  14±8 ,0.05  
gga*-47
N N
CN c18h27n3 285.43 4.57 √  0.4±0.5  
gga*-48
N N
OH c17h28n2O 276.42 4.01 √ √ 0.5±0.3  
gga*-49 N O c15h23nO 233.35 4.37 √  0.4±0.2  
gga*-50
N N
F c21h27Fn2 326.45 6.35 √  0.3±0.2  
gga*-51
N N
F c21h27Fn2 326.45 6.35 √  0.6±0.4  
gga*-52
N N
CN c22h27n3 333.47 6.23 √  0.4±0.2  
isosters gga*-53 O
N
H
c12h21nO 195.3 2.04 √ √ 0.6±0.3  
gga*-54 O
N
H
N
H
c13h24n2O 222.34 2.29 √ √ 0.4±0.3  
gga*-55 O
F N
H
N
H
c17h23Fn2O 290.38 3.77 √ √ 0.3±0.2  
gga*-56 O
O
HO N
H
c14h23nO3 253.34 1.71 √ √ 33±8 ,0.01 no  
gga*-57 212 c14h21nO2 235.32 1.96 √ √ 90±12 ,0.001 Yes ,0.0001  no
gga*-58 1 2 1+ c14h26n2O 238.37 1.86 √ √ 95±14 ,0.001 Yes ,0.0001 no  Yes ,0.01
gga*-59 622 1+ c11h21nO2s 231.35 1.59 √ √ 157±19 ,0.0001 Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
gga*-60 6)& 22 1+ c11h18F3nO2s 285.33 3.77 √ √ 162±21 ,0.0001 Yes ,0.0001 Yes ,0.0001 Yes ,0.01
gga*-61 622 1+ c17h25nO2s 307.45 4.26 √ √ 15±5 ,0.05  
gga*-62 622 2(W2 c15h26O4s 302.43 2.14 √  0.3±0.2  
gga*-63 62 22 1+ c13h23nO3s 273.39 0.69 √ √ 0.4±0.3  
(Continued)
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Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-64 2 22+ 2 c19h16O4 308.33 2.97 √ √ 0.4±0.4  
gga*-65 +22 2 c16h28O3 268.39 3.33 √ √ 0.6±0.3  
gga*-66 +2 c13h24O 196.33 3.5 √ √ 0.5±0.1  
gga*-67 2 1+ c14h25nO 223.45 3.11 √ √ 13±3 ,0.05  
gga*-68 2 2 c12h20O2 196.29 2.72 √  0.3±0.1  
gga*-69 O
O
N
c16h27nO2 265.39 3.3 √  0.3±0.4  
gga*-70 O
O OH
c12h20O3 212.29 1.66 √ √ 15±4 ,0.05  
gga*-71 O
O O O
c17h28O4 296.4 2.86 √  17±6 ,0.05  
not in a group gga*-72 O O
O
HO
c11h12O4 208.21 1.28 √ √ 33±8 ,0.01 no  
gga*-73
O
O
O
HO
O c19h30O5 338.44 3.3 √  0.6±0.2  
gga*-74 O
N
O
HO
c15h25nO3 267.36 3.14 √ √ 0.4±0.2  
gga*-75
O
O
(E)
(S)
N
H
H
N
c15h26n2O2 266.38 1.38 √ √ 45±6 ,0.001 no  
gga*-76 O
N
H
EtO
O
c14h23nO3 253.34 2.42 √ √ 0.2±0.1  
gga*-77 O
N
H
O
EtO
c15h25nO3 267.36 2.36 √ √ 0.5±0.1 ,0.05  
gga*-78 OOH
N
H
c17h23nO2 273.37 3.55 √ √ 0.6±0.4  
gga*-79
O
O c4h5O2 88.11 0.29 √  22±5 ,0.05  
gga*-80 O
O
N
c18h31nO2 293.44 4.13 √  0.7±0.5  
gga*-81 22 21 c22h37nO3 363.53 4.69 √  0.3±0.1        
Notes: The table provides the information of all subsequent experiments. The first columns give information on the first experiments where all compounds were used,  
the later experiments are shown in the later columns, where not all compounds were used. When information is given for a certain column, the compound is used, and  
when a cell is blank, the compound is not tested or used for that experiment.
Abbreviations: caT, calcium transient; Fa, farnesylacetone; gga, geranylgeranylacetone.
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Table 2 (Continued)
Compound Physicochemical properties HL-1 mouse atrial cardiomyocytes Drosophila melanogaster
Structural formula Molecular 
formula
Molecular 
weight
LogP H-bond 
acceptor
H-bond 
donor
HSPA1A boosting (protein) CaT (pretreatment) CaT (posttreatment) Contractile function
Fold 
induction ± SD
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value Protection 
(yes/no)
P-value
gga*-64 2 22+ 2 c19h16O4 308.33 2.97 √ √ 0.4±0.4  
gga*-65 +22 2 c16h28O3 268.39 3.33 √ √ 0.6±0.3  
gga*-66 +2 c13h24O 196.33 3.5 √ √ 0.5±0.1  
gga*-67 2 1+ c14h25nO 223.45 3.11 √ √ 13±3 ,0.05  
gga*-68 2 2 c12h20O2 196.29 2.72 √  0.3±0.1  
gga*-69 O
O
N
c16h27nO2 265.39 3.3 √  0.3±0.4  
gga*-70 O
O OH
c12h20O3 212.29 1.66 √ √ 15±4 ,0.05  
gga*-71 O
O O O
c17h28O4 296.4 2.86 √  17±6 ,0.05  
not in a group gga*-72 O O
O
HO
c11h12O4 208.21 1.28 √ √ 33±8 ,0.01 no  
gga*-73
O
O
O
HO
O c19h30O5 338.44 3.3 √  0.6±0.2  
gga*-74 O
N
O
HO
c15h25nO3 267.36 3.14 √ √ 0.4±0.2  
gga*-75
O
O
(E)
(S)
N
H
H
N
c15h26n2O2 266.38 1.38 √ √ 45±6 ,0.001 no  
gga*-76 O
N
H
EtO
O
c14h23nO3 253.34 2.42 √ √ 0.2±0.1  
gga*-77 O
N
H
O
EtO
c15h25nO3 267.36 2.36 √ √ 0.5±0.1 ,0.05  
gga*-78 OOH
N
H
c17h23nO2 273.37 3.55 √ √ 0.6±0.4  
gga*-79
O
O c4h5O2 88.11 0.29 √  22±5 ,0.05  
gga*-80 O
O
N
c18h31nO2 293.44 4.13 √  0.7±0.5  
gga*-81 22 21 c22h37nO3 363.53 4.69 √  0.3±0.1        
Notes: The table provides the information of all subsequent experiments. The first columns give information on the first experiments where all compounds were used,  
the later experiments are shown in the later columns, where not all compounds were used. When information is given for a certain column, the compound is used, and  
when a cell is blank, the compound is not tested or used for that experiment.
Abbreviations: caT, calcium transient; Fa, farnesylacetone; gga, geranylgeranylacetone.
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lated upon a HS, HSPA1A was used as a read-out. When non-
stressed control HL-1 cardiomyocytes were treated for 6 hours 
with 10 µM GGA or GGA-derivatives, a minor induction of 
HSPA1A expression was observed by Western blot analysis 
(Figure S1). Posttreatment with 10 µM GGA or eighty-one 
GGA-derivatives after a mild, nonlethal HS (10 minutes 
44°C, 10 minutes recovery 37°C) revealed 30 derivatives 
that significantly elevated HSPA1A expression compared to 
control. The HSPA1A boosting effect of GGA-derivatives 
was comparable to or significantly larger compared to GGA 
(Figure 2A and B). The HSPA1A boosting effect could not 
be linked to a specific group of molecular structures of GGA-
derivatives (Figure S2). Next to boosting of HSPA1A expres-
sion levels, GGA-derivatives elevated mRNA expression of 
HSF1-mediated HSPs, including HSPA1A, HSPB1, DNAJB1 
and HSPCA, while mRNA levels of the non-HSF1-related 
HSPA5 were unaffected (Figure S3). Together, the data sug-
gest that GGA and 30 GGA-derivatives boost HSP expression 
in HL-1 cardiomyocytes most likely via HSF1 regulation. 
At identical concentrations, seven GGA-derivatives boosted 
protein abundance of HSPA1A to levels exceeding those of 
GGA (Figure 2B).
gga and gga-derivatives protect 
against caT loss in tachypaced hl-1 
cardiomyocytes
To examine whether GGA-derivatives, like GGA, protect 
against contractile dysfunction, HL-1 cardiomyocytes were 
pretreated with 12 GGA-derivatives with strong HSPA1A-
boosting properties (Table 3) for 8 hours, followed by 
&RQWURO **$ **$ **$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 **$ **$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Figure 2 gga and gga-derivatives induce hsPa1a expression in hl-1 cardiomyocytes pretreated with gga and gga-derivatives upon a mild hs.
Notes: (A) representative example of a Western blot for hsPa1a and gaPDh of hl-1 cardiomyocytes pretreated with DMsO (control), 10 µM gga and 10 µM 
gga*-19, -20, -21, -27, -31, -59, -60, -61, and -67 upon a mild hs. (B) Quantified Western blot results for HSPA1A relative to GAPDH for GGA and GGA-derivatives. 
Mean ± seM, * is P,0.05, ** is P,0.01, *** is P,0.001, and **** is P,0.0001 compared to control cardiomyocytes and # is P,0.05 and ## is P,0.01 compared to gga.
Abbreviations: DMsO, dimethylsulfoxide; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; gga, geranylgeranylacetone; hs, heat shock.
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Table 3 Overview of cardioprotective effects of the most potent hsPa1a inducers in hl-1 cardiomyocyte model and Drosophila
GGA-
derivative
HL-1 mouse cardiomyocytes Drosophila melanogaster
CaT (pretreatment) CaT (posttreatment) Contractile function
Protection vs 
control (yes/no)
P-value Protection vs 24 hours 
recovery (yes/no)
P-value Protection vs 
control (yes/no)
P-value
gga Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
gga*-14 no – – – – –
gga*-18 Yes ,0.0001 – – no –
gga*-26 Yes ,0.01 – – – –
gga*-28 Yes ,0.0001 no – no –
gga*-31 Yes ,0.0001 Yes ,0.05 Yes ,0.05
gga*-32 Yes ,0.05 – – – –
gga*-56 no – – – – –
gga*-57 Yes ,0.0001 – – no –
gga*-58 Yes ,0.0001 no – Yes ,0.01
gga*-59 Yes ,0.0001 Yes ,0.0001 Yes ,0.0001
gga*-60 Yes ,0.0001 Yes ,0.0001 Yes ,0.01
gga*-72 no – – – – –
Abbreviations: –, not applicable; caT, calcium transient; gga, geranylgeranylacetone.
8 hours TP (4.5 Hz) or normal pacing (1 Hz). Previous 
studies revealed that GGA induces HSPA1A expression 
up to 24 hours upon treatment.7,16 Contractile function was 
determined by measuring CaT. TP induced significant CaT 
loss compared to normal pacing, which was prevented by 
GGA and GGA*-18, -26, -28, -31, -32, -57, -58, -59, and -60 
(Figure 3).
suppression of hsPB1 abrogated the 
protective effect of the gga-derivative 
in hl-1 cardiomyocytes
Since previous studies implicate HSPB1 as a crucial HSP in 
the protective effect of GGA against TP-induced CaT loss,7 
we tested whether the protective effect of GGA-derivatives 
acts via HSPB1. Hereto, HL-1 cardiomyocytes were trans-
fected with siRNA-HSPB1 constructs or control, followed 
by GGA or GGA-derivative treatment for 8 hours, and TP 
or nonpacing for 8 hours. siRNA treatment successfully 
suppressed HSPB1 24 hours after transfection (Figure 4A). 
siRNA-mediated suppression of HSPB1 levels completely 
abrogated the protective effect of GGA or GGA-derivatives 
(Figure 4B and C), indicating that their protective effect is 
dependent on HSPB1.
gga and gga-derivatives protect 
against contractile dysfunction 
in Drosophila
Next, we assessed whether protective GGA-derivatives, 
identified in HL-1 cardiomyocytes, also protected Drosophila 
from TP-induced contractile dysfunction. Hereto, the seven 
most protective GGA-derivatives (GGA*-18, -28, -31, -57, 
-58, -59, and -60, Table 3) and, as a negative control, one 
non-HSPA1A boosting GGA-derivative (GGA*-16), were 
examined. All compounds were without effect on basal heart 
function (Figure S4). TP for 20 minutes at 5 Hz induced a 
significant dysfunction of heart wall contractility (Figure 5 
and Videos S1 and S2), which was prevented by GGA and 
GGA*-31, -58, -59, and -60 (Figure 5 and Videos S3 and S4). 
Expectedly, GGA*-16 was without effect, because of its 
lack of protection in HL-1 cardiomyocytes (Figure 5). These 
findings indicate that four GGA-derivatives protect against 
TP-induced contractile dysfunction in the Drosophila model 
for AF.
gga-derivatives restore contractile 
function after TP
Since most patients with AF reveal cardiomyocyte remod-
eling at the moment of diagnosis, compounds that restore 
contractile function are of high clinical relevancy. Therefore, 
GGA-derivatives were tested for their ability to restore CaT 
loss in the tachypaced HL-1 cardiomyocyte model. Hereto, 
HL-1 cardiomyocytes were tachypaced at 4.5 Hz for 8 hours, 
followed by 24 hours recovery and treatment with GGA 
or GGA-derivatives (GGA*-28, -31, -58, -59, and -60, 
Table 3). TP resulted in a significant CaT loss, which even 
further decreased after 24 hours recovery (Figure 6A and B). 
However, tachypaced HL-1 cardiomyocytes posttreated with 
10 µM GGA*-31, -59, or -60, or GGA significantly restored 
CaT, compared to untreated HL-1 cardiomyocytes. Restora-
tion of CaT by GGA and GGA*-59 was significantly larger 
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than GGA*-31 and -60 at 10 µM, while GGA*-28 and -58 
did not restore contractile function (Figure 6A and B). These 
findings indicate that GGA and GGA*-59 restore cardiomyo-
cyte function after TP, whilst GGA*-28, -31, -58, and -60 
do not or to a lesser extent.
hsF1 activation by gga-derivative
Finally, to address the mode of action of the top functional 
GGA-derivative, we assessed the effect of GGA*-59 
(10 µM) on the main effector of GGA effects, ie, HSF1 
phosphorylation status,33 by assessing HSF1 mobility on 
SDS-PAGE. HS induces activation of HSF1, as indicated 
by decreased mobility because of HSF1 hyperphosphoryla-
tion,34 lasting for up to 1 hour (Figure 7A and B). Treatment 
with GGA*-59 enhances the ratio of hyperphosphorylated 
HSF1/HSF1 (Figure 7A and B), thus further enhanc-
ing HSF1 activation. In accord, treatment with GGA*-
59 enhances subsequent HSPA1A protein expression 
(Figure 7C and D). These data signify that GGA*-59 boosts 
HSPs via HSF1 activation.
Discussion
Previous studies identified the HSP-booster GGA to protect 
against contractile dysfunction and remodeling in experimen-
tal models for AF.7,16,25,26,35 However, its lipophilic character 
hampers systemic bioavailability in patients.30 Since HSPs 
may limit AF progression and possibly reverse remodeling 
in clinical AF, we here report on the structural properties 
of novel derivatives of GGA. Eighty-one GGA-derivatives 
were synthesized by shortening the lipophilic backbone of 
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&RQ 73 PV&D7
73**$ 73**$ 73**$73**$&RQWURO 73$%
Figure 3 gga and gga-derivatives protect against caT loss in hl-1 cardiomyocytes.
Notes: compared to normal-paced controls, TP induces a loss in caT amplitude which is protected by pretreatment with gga and gga-derivatives. (A) illustrations of 
caT tracers of control hl-1 cardiomyocytes (paced at 1 hz) and of hl-1 cardiomyocytes after 8 hours of TP (4.5 hz) pretreated with DMsO (TP), 10 µM gga, or 10 µM 
gga*-18, -59, or -60. (B) Quantified CaT amplitude of HL-1 cardiomyocytes treated with DMSO (Control), 10 µM gga or 10 µM gga-derivatives. nine gga-derivatives, 
namely GGA*-18, -26, -28, -31, -32, -57, -58, -59, and -60, show significant protection against CaT loss. **** is P,0.0001 compared to normal-paced control, # is P,0.05, ## 
is P,0.01, and #### is P,0.0001 compared to tachypaced control. The first control is a normal-paced control, treated with DMSO, as indicated by the line above the column 
with ‘con’ above it. The second control is a tachypaced control, treated with DMsO, indicated with the line above the columns of tachypaced cells with ‘TP’ above it.
Abbreviations: caT, calcium transient; con, control; DMsO, dimethylsulfoxide; gga, geranylgeranylacetone; TP, tachypacing.
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Figure 4 sirna against hsPB1 abrogated the protective effect of the gga-derivatives in hl-1 cardiomyocytes.
Notes: (A) successful suppression of hsPB1 expression in hl-1 cardiomyocytes. (B) caT tracers of control hl-1 cardiomyocytes (paced at 1 hz) and of hl-1 cardiomyocytes 
after 8 hours of TP (4.5 hz) pretreated with DMsO (control), 10 µM gga or 10 µM gga*-26 or 10 µM gga*-28 show, that hsPB1 knock down abrogate the protective 
effects of the compounds. (C) Quantified CaT amplitude of HL-1 cardiomyocytes pretreated with DMSO (Control), 10 µM gga or 10 µM gga*-26 or 10 µM gga*-28 
with/without sirna against hsPB1. *** is P,0.001 compared to normal-paced control cardiomyocytes and # is P,0.05 compared to tachypaced control cardiomyocytes. 
The first control is a normal-paced, DMSO treated control, indicated by the line above with ‘Con’. The second control is a tachypaced, DMSO treated, control, indicated 
by the line above the bars with ‘TP’.
Abbreviations: caT, calcium transient; con, control; DMsO, dimethylsulfoxide; gga, geranylgeranylacetone; TP, tachypacing.
GGA and modifying the east, west, and central part of the 
molecule. Seven out of 30 GGA-derivatives that significantly 
induced HSPA1A expression after a mild HS were superior to 
GGA, at the given dose, in terms of higher HSPA1A protein 
expression. Nine out of the 12 most potent HSPA1A boosters 
(GGA*-18, -26, -28, -31, -32, -57, -58, -59, and -60) protected 
against TP-induced loss of CaT in HL-1 cardiomyocytes 
and four GGA-derivatives (GGA*-31, -58, -59, and -60) 
also protected against contractile dysfunction in Drosophila 
prepupae, which consumed GGA-derivative supplemented 
food during their larval stage as a pretreatment. Protective 
effects of GGA-derivatives seem dependent of HSPB1, 
because siRNA against HSPB1 abrogates the protection 
from TP-induced CaT loss, as previously found for GGA.7 
Intriguingly, posttreatment, ie treatment with GGA and 
GGA-derivatives (GGA*-31, -59, and -60 of which GGA*-
59 was superior compared to GGA*-31 and -60) directly 
after TP for the duration of 24 hours, restored TP-induced 
CaT loss in HL-1 cardiomyocytes. Not all GGA-derivatives 
which revealed protective effects against CaT loss in HL-1 
cardiomyocytes were also protective upon pretreatment in 
tachypaced Drosophila or could restore cardiomyocyte func-
tion upon 24 hours posttreatment (Table 3). This may be due 
to reduced stability of the derivative. Future studies should 
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Figure 5 gga and gga-derivatives protect against contractile dysfunction in Drosophila.
Notes: TP (5 Hz) induces significant heart wall contractile dysfunction in Drosophila. Drosophila prepupae pretreated with 100 µM gga, 100 µM gga*-31, -58, -59, or -60 
were protected against TP-induced contractile dysfunction, while gga*-16, -18, -28, or -57 were not protective. Mean ± seM, **** is P,0.0001 compared to nonpaced 
control prepupae, # is P,0.05, ## is P,0.01 and #### is P,0.0001 compared to tachypaced control prepupae. The first control is a nonpaced control, treated with DMSO. 
The second control is a tachypaced control, treated with DMsO.
Abbreviations: con, control; gga, geranylgeranylacetone; TP, tachypacing. 
&RQ &RQ **$ **$ **$ **$ **$ **$ **$ **$ **$
&RQWUDFWLOHIXQF
WLRQ    &RQ 73
73
73UHFRYHU\**$73UHFRYHU\**$ &D7 PV
73UHFRYHU\
73UHFRYHU\**$73UHFRYHU\**$
&RQWURO
73UHFRYHU\**$73UHFRYHU\**$
$  &RQ 73
   ∆&D7  &RQ &RQ5HFRYHU\ **$**$**$**$**$**$
%
Figure 6 gga and gga*-31, -59, and -60 accelerate restoration of caT loss in hl-1 atrial cardiomyocytes after 24 hours posttreatment, compared to the nontreated 
cardiomyocytes.
Notes: (A) caT of control, TP, TP with 24 hours recovery and TP with 24 hours recovery in combination with posttreatment with 10 µM gga or gga-derivatives. 
(B) Quantified data revealing that GGA and GGA*-31, -59, and -60 accelerate restoration of CaT loss in HL-1 atrial cardiomyocytes after 24 hours posttreatment. **** is 
P,0.0001 compared to control cardiomyocytes, # is P,0.05; #### is P,0.0001 compared to tachypaced cardiomyocytes that recovered for 24 hours and † is P,0.05 and 
†††† is P,0.0001 compared to GGA*-59. The first control is a normal-paced control, treated with DMSO, indicated by the line above it with ‘Con’. The second control is a 
tachypaced control, treated with DMsO, indicated by the line above the bars with ‘TP’.
Abbreviations: caT, calcium transient; con, control; gga, geranylgeranylacetone; TP, tachypacing.
elucidate the pharmacokinetics of potent GGA-derivatives. 
Nevertheless, we identified one GGA-derivative, GGA*-59, 
with improved physicochemical properties, that boosts HSPs, 
and both protects from TP-induced contractile dysfunc-
tion, and restores this after TP. Consequently, our analysis 
indicates GGA*-59 as a GGA-derivative with substantial 
potential for clinical applications.
improved physicochemical properties of 
gga-derivatives
The clinical use of GGA to treat AF is hampered by its lipo-
philicity and therefore high dosages have to be used.7,36 Here 
we report a library of GGA-derivatives, created considering 
the Lipinski rule of five,32 to achieve more druggable analogs 
of GGA while maintaining in vitro/in vivo activity. The 
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Figure 7 gga*-59 enhances hsF1 hyperphosphorylation and subsequent hsPa1a boosting in hl-1 cardiomyocytes.
Notes: (A) gga*-59 enhances hyperphosphorylation of hsF1, shown by decreased mobility of hsF1 in the gel. (B) gga*-59 enhances the ratio of hyperphosphorylated 
HSF1/HSF1 (quantified higher band/lower band). (C) representative Western blot showing hsPa1a expression levels for the conditions as indicated. (D) gga*-59 
treatment enhances hsPa1a protein expression levels after 6 hours treatment, compared to nontreated heat shocked control cardiomyocytes. * is P,0.05 compared to 
control, # is P,0.05 and #### is P,0.0001 compared to nontreated cardiomyocytes at 1 hour and 6 hours, respectively.
Abbreviations: gga, geranylgeranylacetone; hsF1, heat shock factor 1; hs, heat shock.
improved physicochemical properties of the GGA-derivatives, 
essentially having LogP values between 0 and 5 and molecular 
weight below 500, increase their solubility and are expected 
to improve passage of lipid bilayers, most likely resulting in 
increased uptake in the intestine and improved distribution to 
the body and cells,32 thereby improving clinical applicability.
The derivatives that boosted HSP expression and pro-
tected against and induced recovery (only GGA*-31, -59, and 
-60) from TP-induced contractile dysfunction were GGA*-
57, -58, -59, and -60 (isosters from GGA), GGA*-14, -18, 
and -26 (“geranyl keto esters”) and GGA*-28 (“a geranyl 
ketone”). Despite the fact that the most favorable compounds 
are divided into groups based on the isosteric (central part) 
and east- and west-side modifications, we were unable to 
attribute this to specific structural features of the compounds. 
Further research/synthesis is needed to expand the hits to 
series of lead compounds with clinical potential.
Preserving proteostasis: possible mode of 
action of gga-derivatives
Given the similarity of the actions of the efficacious GGA-
derivatives to GGA effects, the most likely mode of action 
of our derivatives comprises their preservation of proteo-
stasis by activation of HSF1 and subsequent boosting of 
HSPs expression. The observed increase in gene expression 
levels of various HSF1-regulated genes by GGA-derivatives, 
including HSPA1A, HSPB1, DNAJB1, HSPCA, and absence 
of increase in the HSF1-independent HSPA5, are similar to 
GGA. In addition, similar to GGA,33 GGA*-59 prolonged 
HSF1 activation, as shown by its increased hyperphosphory-
lation. Collectively, these data indicate that GGA-derivatives 
boost HSP expression by prolonging HSF1 activation, result-
ing in its extension of binding to the HS element (HSE) in 
the promotor regions of hsp genes, thus prolonging hsp gene 
transcription and HSP protein expression. At least, 30 GGA-
derivatives significantly induced HSPA1A protein expres-
sion of which seven demonstrated improved HSP-boosting 
properties compared to GGA.
The precise nature of the molecular pathway by which 
GGA and GGA-derivatives prolong hyperphosphorylation 
of HSF1 is still subject of speculation. It is known that 
geranyl-groups act as posttranslational modifiers of proteins, 
and thereby regulate protein function.37 Natural occurring 
prenylation with C15 (farnesyl) or C20 (geranylgeranyl) 
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isoprenoids, derived from mevalonic acid, mediates trans-
location of RhoA to the plasma membrane and activation of 
the downstream pathway.38–40 In addition, active RhoA was 
found to abrogate the HSF1 transcriptional activity by sup-
pressing HSF1 binding to the HSE of hsp genes.34 Therefore, 
one of the possible mechanisms constitute the competition of 
GGA and GGA-derivatives with endogenous geranyl-groups, 
which could lead to inhibition of RhoA activation, resulting 
in enhanced binding of HSF1 to the HSE region.41,42 How-
ever, this should be further investigated by genetic ablation, 
competition and enhanced binding experiments.
how hsPs protect the cardiomyocytes
Irrespective of the precise molecular pathways affected by 
GGA and GGA-derivatives, their protective action seems 
to be critically dependent on boosting HSPB1, because the 
protective effect was abrogated by siRNA against HSPB1. 
In previous studies HSPB1 overexpression protected from 
TP-induced contractile dysfunction and structural remod-
eling in HL-1 and Drosophila models for AF.7,26 HSPB1 
stabilizes sarcomeric proteins, including alpha-actinin and 
actin, prevents their disruption and enhances recovery after 
disruption.20,43 Furthermore, HSPB1 (co)-localizes with 
myosin in HL-1 cardiomyocytes and at myofilaments in 
human atrial myocytes and thereby potentially conserve 
myofibrils.16 Therefore, HSPB1 may shield the contractile 
proteins from AF-induced cleavage by cysteine proteases, 
such as calpain.26,44,45 Given that GGA-derivatives enhance 
HSP expression and protect from TP-induced contractile 
dysfunction, which is abrogated after suppression of HSPB1, 
we appoint HSPB1 to be one of the most important players 
in the cardioprotective effect of GGA-derivatives.
Therapeutic application of hsP-inducing 
compounds
In this study, HSP-inducing compounds were shown to 
prevent and reverse contractile dysfunction in experimental 
models for AF, which is promising for treating clinical 
AF, since patients diagnosed with AF already suffer from 
AF-related electropathology. Besides, comparable to GGA, 
the GGA-derivatives only boosted the HSR in cardiomyo-
cytes pretreated with a mild, sub-lethal HS and not under 
nonstressed conditions, indicating that augmentation of the 
HSR by GGA and its derivatives is confined to stressed cells. 
In clinical perspective, this might indicate that side effects 
due to enhancing HSR are limited, if existent at all. Accord-
ingly, it would be of interest to test suitable GGA-derivatives 
for future applications in the clinic. This would initially 
require testing of selected GGA-derivatives in a larger in vivo 
model for AF, such as the atrial pacemaker stimulated dog 
model for AF. Although the experimental models used in the 
current study were suitable to extract potent HSP boosters 
from the 81 synthesized GGA-derivatives, they do not fully 
reflect the complexity of electropathology in AF, making 
extrapolation to clinical AF beyond reach. Furthermore, 
pharmacokinetics need to be further explored in in vivo 
models to investigate bioavailability of the derivatives. Yet, 
GGA itself could already be further explored in clinical 
AF despite its less favorable physicochemical therapeutic 
profile, since the compound is already marketed in various 
Asian countries and considered a safe drug. As a proof of 
concept, a first study may explore whether GGA induces 
HSP expression in atrial tissue of AF patients and whether 
induced HSP expression correlates to reduced AF burden. 
Further research is necessary to test whether GGA or GGA-
derivatives can prevent progression of clinical AF and reverse 
existing electropathology in clinical AF.
Conclusion
We identified multiple GGA-derivatives, especially 
GGA*-59, with an improved physicochemical profile and 
full preservation of HSP-boosting capacities, including both 
cardioprotective properties and acceleration of recovery 
from contractile dysfunction in an experimental model of 
AF. As such, this study substantiates our previous findings 
that HSP induction has high potential as a novel approach to 
prevent progression of AF and reverse remodeling.
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